.jpg "Editas Medicine Inc (NASDAQ: EDIT)")
Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Editas Medicine Inc (EDIT) today. The company’s shares opened today at $23.51.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 5.4% and a 48.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Allogene Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Editas Medicine Inc with a $55 average price target, a 133.9% upside from current levels. In a report released today, Chardan Capital also reiterated a Buy rating on the stock with a $55 price target.
See today’s analyst top recommended stocks >>
Based on Editas Medicine Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $15.24 million. In comparison, last year the company had a GAAP net loss of $36.19 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9).
